Pharma's Top 10 Blockbuster Drugs(Highest sale)

(1) Lipitor - Pharma's Bestselling Blockbuster Drugs

Maker: Pfizer
Sales Rank: 1
Technology: Chiral chemistry
2009 Sales: $12.5 billion

Indications: Hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb) to reduce total cholesterol

Lipitor News:Pfizer recalls more smelly Lipitor bottles
Analysts: Lipitor may live longer than we think
Generics firms close in on Lipitor

(2)  Plavix

Maker: Bristol-Myers Squibb and Sanofi-Aventis
Sales Rank: 2
Technology: Small molecule
2009 Sales: $9.5 billion

Indications: Heart attack and stroke prevention

Plavix News:Sanofi, BMS win $442M in damages from Apotex
Will gene-testing be a blood-thinner battleground?
Will Plavix black box prompt gene tests?

(3) Advair 

Maker: GlaxoSmithKline
Sales Rank: 3
Technology: Small Molecule
2009 Sales: $7.7 billion 

Indications: Asthma and COPD

Advair News:
GSK chief was right about tough-to-copy Advair
German court rebuffs GSK on Advair patent
Witty: No rivals coming for Advair

(4) Enbrel

Maker: Amgen
Sales Rank: 4
Technology: Recombinant product
2009 Sales: $6.2 billion 

Indications: Rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, chronic plaque psoriasis

Enbrel News: U.K. trust sues for Enbrel royalties
TNF blockers get child cancer warning

(5) Diovan

Maker: Novartis
Sales Rank: 5
Technology: Small Molecule
2009 Sales: $6.0 billion 

Indications: Hypertension and congestive heart failure

Diovan News: FDA launches safety review of ARBs
With pediatric OK, Diovan's in line for longer exclusivity
ARBs like Diovan may prevent, treat Alzheimer's

(6)  Remicade

Maker: Johnson & Johnson
Sales Rank: 6
Technology: Monoclonal antibody
2009 Sales: $5.9 billion 

Indications: Plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults, pediatric Crohn's disease, ulcerative colitis, and ankylosing spondylitis

Remicade News:J&J, Merck postpone Remicade ruling to 2011
Merck's Remicade face-off puts $2.7B at risk

(7)  Avastin

Maker:  Roche/Genentech
Sales Rank: 7
Technology: Monoclonal antibody
2009 Sales: $5.7 billion 

Indications: Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Glioblastoma, Metastatic Kidney Cancer

Avastin News:Avastin, Tamiflu depress Roche sales by 7%
Avastin, Erbitux rack up data gains
Small study affirms Avastin as AMD treatment

(8)  Rituxan

Maker:  Roche/Genentech
Sales Rank: 8
Technology: Monoclonal antibody
2009 Sales: $5.6 billion 

Indications: Non-Hodgkin's lymphoma, Chronic Lymhocytic leukemia, Rheumatoid arthritis

Rituxan News:Rituxan, Revlimid win in maintenance trials
Rituxan wins FDA nod for leukemia use

(9)  Humira

Maker: Abbott Pharmaceuticals
Sales Rank: 9
Technology: Monoclonal antibody
2009 Sales: $5.5 billion 

Indications: Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis (AS) in adults, Crohn's disease, Plaque psoriasis

Humira News:Abbott fights $1.67B Humira verdict in court
Humira elbows Avastin aside in top-drug ranking

(10)  Seroquel

Maker: AstraZeneca
Sales Rank: 10
Technology: Small molecule
2009 Sales: $5.1 billion 

Indications: Major depressive disorder, Acute depressive episodes in bipolar disorder, Acute manic or mixed episodes in bipolar disorder alone or with lithium or divalproex; Long-term treatment of bipolar disorder with lithium or divalproex, and Schizophrenia


Seroquel News:Judges offer AZ more time to settle Seroquel suits
AZ resolves 17,500 Seroquel claims for $198M
NYT: AstraZeneca in $520M Seroquel settlement